Abstract
OrthoLogic (formerly Chrysalis) is developing Chrysalin, a synthetic 23-amino acid peptide that mimics a portion of human thrombin. The compound is in phase II clinical trials for the potential treatment of diabetic foot ulcers and phase III trials for cartilage repair and bone fractures.
Original language | English (US) |
---|---|
Pages (from-to) | 264-272 |
Number of pages | 9 |
Journal | Current Opinion in Molecular Therapeutics |
Volume | 7 |
Issue number | 3 |
State | Published - Jun 2005 |
Externally published | Yes |
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
- Pharmacology
- Drug Discovery
- Genetics(clinical)